Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $71.5 million.

  • Zenas BioPharma's Net Cash Flow fell 5939.28% to $71.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$244.4 million, marking a year-over-year decrease of 18492.87%. This contributed to the annual value of $262.7 million for FY2024, which is 261900.29% up from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's Net Cash Flow is $71.5 million, which was down 5939.28% from -$152.3 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Net Cash Flow high stood at $176.2 million for Q3 2024, and its period low was -$152.3 million during Q2 2025.
  • Its 3-year average for Net Cash Flow is $5.4 million, with a median of -$17.5 million in 2023.
  • The largest annual percentage gain for Zenas BioPharma's Net Cash Flow in the last 5 years was 5939.28% (2025), contrasted with its biggest fall of 52430.84% (2025).
  • Over the past 3 years, Zenas BioPharma's Net Cash Flow (Quarter) stood at -$15.4 million in 2023, then crashed by 163.43% to -$40.4 million in 2024, then soared by 276.91% to $71.5 million in 2025.
  • Its Net Cash Flow stands at $71.5 million for Q3 2025, versus -$152.3 million for Q2 2025 and -$123.2 million for Q1 2025.